Received Apr 28, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| RSV | RSV (AREXVY) | GLAXOSMITHKLINE BIOLOGICALS | UNK | UNK | — |
fever; body aches; throwing up; headache; This non-serious case was reported by a consumer via interactive digital media and described the occurrence of fever in a patient who received RSVPreF3 adjuvanted (Arexvy) for prophylaxis. On an unknown date, the patient received Arexvy. On an unknown date, an unknown time after receiving Arexvy, the patient experienced fever (Verbatim: fever), general body pain (Verbatim: body aches), vomiting (Verbatim: throwing up) and headache (Verbatim: headache). The outcome of the fever, general body pain, vomiting and headache were resolved (duration 1 week). It was unknown if the reporter considered the fever, general body pain, vomiting and headache to be related to Arexvy. It was unknown if the company considered the fever, general body pain, vomiting and headache to be related to Arexvy. Additional Information: GSK Receipt Date: 18-APR-2025 This case was reported by a consumer via (Open field AE monitoring) interactive digital media. The patient just got the shot and reactions were more severe, fever, body aches, throwing up, headache for a week.